1. Scrip
  2. >>Business
  3. >>Financing

Abcuro Raises $155m Series B Round For Clinical-Stage T-Cell Depleter

Late-Stage Asset Attracts ‘Robust’ Investors

 
• By Mandy Jackson

The company’s fresh cash will fund readouts for lead drug candidate ABC008 from a pivotal Phase II/III trial in inclusion body myositis and from Phase I/II studies in two other rare indications.

venture capital, text on white paper on wood background
Abcuro moved ABC008 into Phase II/III prior to its series B round • Source: Shutterstock

Abcuro, Inc. has come a long way since it raised $42m in series A-1 venture capital at the start of 2021 and it plans to take its lead drug candidate even further with $155m in series B funding that the company announced on 17 August. ABC008 moved through Phase I/II testing in inclusion body myositis (IBM) and into a Phase II/III clinical trial in IBM and now the drug candidate has funding to see it through to the readout of that pivotal study and completion of Phase I/II trials in two additional rare indications.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.